Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution

Authors: Daniel Habermehl, Klaus K Herfarth, Justo Lorenzo Bermejo, Holger Hof, Stefan Rieken, Sabine Kuhn, Thomas Welzel, Jürgen Debus, Stephanie E Combs

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Background

Local ablative therapies such as stereotactically guided single-dose radiotherapy or helical intensity-modulated radiotherapy (tomotherapy) with high single-doses are successfully applied in many centers in patients with liver metastasis not suitable for surgical resection. This study presents results from more than 10 years of clinical experience and evaluates long-term outcome and efficacy of this therapeutic approach.

Patients and methods

From 1997 to 2009 a total of 138 intrahepatic tumors of 90 patients were irradiated with single doses of 17 to 30 Gy (median dose 24 Gy). Median age of the patients was 64 years (range 31–89 years). Most frequent underlying tumor histologies were colorectal adenocarcinoma (70 lesions) and breast cancer (27 lesions). In 35 treatment sessions multiple targets were simultaneously irradiated (up to four lesions at once). Local progression-free (PFS) and overall survival (OS) after treatment were investigated using uni- and multiple survival regression models.

Results

Median overall survival of all patients was 24.3 months. Local PFS was 87%, 70% and 59% after 6, 12 and 18 months, respectively. Median time to local progression was 25.5 months. Patients with a single lesion and no further metastases at time of RT had a favorable median PFS of 43.1 months according to the Kaplan-Meier estimator. The type of tumor showed a statistical significant influence on local PFS, with a better prognosis for breast cancer histology than for colorectal carcinoma in uni- and multiple regression analysis (p = 0.05). Multiple regression analysis revealed no influence of planning target volume (PTV), patient age and radiation dose on local PFS. Treatment was well tolerated with no severe adverse events.

Conclusion

This study confirms safety of SBRT in liver lesions, with 6- and 12 months local control of 87% and 70%. The dataset represents the clinical situation in a large oncology setting, with many competing treatment options and heterogeneous patient characteristics.
Appendix
Available only for authorised users
Literature
1.
Bengmark S, Hafstrom L: The natural history of primary and secondary malignant tumors of the liver I. the prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969,23(1):198-202. 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-JCrossRefPubMed
2.
Dawson LA, Ten Haken RK: Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005,15(4):279-283. 10.1016/j.semradonc.2005.04.005CrossRefPubMed
3.
Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008,247(1):125-135. 10.1097/SLA.0b013e31815aa2c2CrossRefPubMed
4.
Chua TC, Saxena A, Liauw W, Chu F, Morris DL: Hepatic resection for metastatic breast cancer: a systematic review. Eur J Cancer 2011,47(15):2282-2290. 10.1016/j.ejca.2011.06.024CrossRefPubMed
5.
Small R, Lubezky N, Ben-Haim M: Current controversies in the surgical management of colorectal cancer metastases to the liver. IMAJ 2007,9(10):742-747.PubMed
6.
Pawlik TM, Schulick RD, Choti MA: Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008,13(1):51-64. 10.1634/theoncologist.2007-0142CrossRefPubMed
7.
Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW: Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006,12(4):318-326. 10.1097/00130404-200607000-00011CrossRefPubMed
8.
Martin RC, Robbins K, Tomalty D, O'Hara R, Bosnjakovic P, Padr R, Rocek M, Slauf F, Scupchenko A, Tatum C: Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009, 7: 80. 10.1186/1477-7819-7-80CrossRefPubMedPubMedCentral
9.
Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K: Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol 2011,21(12):2584-2596. 10.1007/s00330-011-2222-3CrossRefPubMed
10.
Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS: Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001,221(1):159-166. 10.1148/radiol.2211001624CrossRefPubMed
11.
Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, et al.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009,27(10):1572-1578. 10.1200/JCO.2008.19.6329CrossRefPubMed
12.
Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, et al.: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009,27(10):1585-1591. 10.1200/JCO.2008.20.0600CrossRefPubMed
13.
Habermehl D, Debus J, Ganten T, Ganten MK, Bauer J, Brecht IC, Brons S, Haberer T, Haertig M, Jaekel O, et al.: Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response. Radiat Oncol 2013,8(1):59. 10.1186/1748-717X-8-59CrossRefPubMedPubMedCentral
14.
Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001,19(1):164-170.PubMed
15.
Wulf J, Hadinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M: Stereotactic radiotherapy of targets in the lung and liver. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 2001,177(12):645-655. 10.1007/PL00002379CrossRef
16.
Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys 2005,62(5):1371-1378. 10.1016/j.ijrobp.2005.01.002CrossRefPubMed
17.
Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H: Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 2006,45(7):823-830. 10.1080/02841860600904854CrossRefPubMed
18.
Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, et al.: Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006,45(7):848-855. 10.1080/02841860600904870CrossRefPubMed
19.
Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, et al.: Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 2006,45(7):831-837. 10.1080/02841860600897934CrossRefPubMed
20.
van der Pool AE, Mendez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, Ijzermans JN: Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010,97(3):377-382. 10.1002/bjs.6895CrossRefPubMed
21.
Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC: Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010,78(2):486-493. 10.1016/j.ijrobp.2009.08.020CrossRefPubMed
22.
Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Hoss A, Schlegel W, Wannenmacher MF: Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys 2000,46(2):329-335. 10.1016/S0360-3016(99)00413-7CrossRefPubMed
23.
Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brugel M, Ziegler SI, Molls M, Schwaiger M, Essler M: Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 2012,188(7):592-598. 10.1007/s00066-012-0094-3CrossRef
24.
Gong GZ, Yin Y, Xing LG, Guo YJ, Liu T, Chen J, Lu J, Ma C, Sun T, Bai T, et al.: RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al.] 2012,188(3):262-268. 10.1007/s00066-011-0044-5CrossRef
25.
Fumagalli I, Bibault JE, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E: A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol 2012, 7: 164. 10.1186/1748-717X-7-164CrossRefPubMedPubMedCentral
26.
Dewas S, Bibault JE, Mirabel X, Fumagalli I, Kramar A, Jarraya H, Lacornerie T, Dewas-Vautravers C, Lartigau E: Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 2012, 7: 166. 10.1186/1748-717X-7-166CrossRefPubMedPubMedCentral
27.
Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007,67(3):793-798. 10.1016/j.ijrobp.2006.10.025CrossRefPubMed
28.
Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, Schwarz RE, Weatherall P, Chinsoo Cho L: Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011,18(4):1081-1087. 10.1245/s10434-010-1405-5CrossRefPubMed
29.
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, et al.: Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 2011,117(17):4060-4069. 10.1002/cncr.25997CrossRefPubMed
30.
Lohr F, Debus J, Frank C, Herfarth K, Pastyr O, Rhein B, Bahner ML, Schlegel W, Wannenmacher M: Noninvasive patient fixation for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1999,45(2):521-527. 10.1016/S0360-3016(99)00190-XCrossRefPubMed
31.
Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK: Analysis of radiation-induced liver disease using the lyman NTCP model. Int J Radiat Oncol Biol Phys 2002,53(4):810-821. 10.1016/S0360-3016(02)02846-8CrossRefPubMed
32.
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991,21(1):109-122. 10.1016/0360-3016(91)90171-YCrossRefPubMed
33.
Ingold JA, Reed GB, Kaplan HS, Bagshaw MA: Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965, 93: 200-208.PubMed
34.
Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE: Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2009,73(5):1414-1424. 10.1016/j.ijrobp.2008.07.032CrossRefPubMed
35.
Hoyer M, Swaminath A, Bydder S, Lock M, Mendez Romero A, Kavanagh B, Goodman KA, Okunieff P, Dawson LA: Radiotherapy for liver metastases: a review of evidence. Int J Radiat Oncol Biol Phys 2012,82(3):1047-1057. 10.1016/j.ijrobp.2011.07.020CrossRefPubMed
36.
Jaffe BM, Donegan WL, Watson F, Spratt JS Jr: Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1968,127(1):1-11.PubMed
37.
Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM: The natural history of hepatic metastases from colorectal cancer. a comparison with resective treatment. Ann Surg 1984,199(5):502-508. 10.1097/00000658-198405000-00002CrossRefPubMedPubMedCentral
38.
Scheele J, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K: Resection of colorectal liver metastases. what prognostic factors determine patient selection? Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2001,72(5):547-560. 10.1007/s001040051345CrossRefPubMed
39.
Jenkins LT, Millikan KW, Bines SD, Staren ED, Doolas A: Hepatic resection for metastatic colorectal cancer. Am Surg 1997,63(7):605-610.PubMed
40.
Lanciano R, Lamond J, Yang J, Feng J, Arrigo S, Good M, Brady L: Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Frontiers in oncology 2012, 2: 23.CrossRefPubMedPubMedCentral
41.
Vautravers-Dewas C, Dewas S, Bonodeau F, Adenis A, Lacornerie T, Penel N, Lartigau E, Mirabel X: Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys 2011,81(3):e39-e47. 10.1016/j.ijrobp.2010.12.047CrossRefPubMed
42.
Milano MT, Katz AW, Schell MC, Philip A, Okunieff P: Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2008,72(5):1516-1522. 10.1016/j.ijrobp.2008.03.044CrossRefPubMed
43.
Wunderink W, Mendez Romero A, Seppenwoolde Y, de Boer H, Levendag P, Heijmen B: Potentials and limitations of guiding liver stereotactic body radiation therapy set-up on liver-implanted fiducial markers. Int J Radiat Oncol Biol Phys 2010,77(5):1573-1583. 10.1016/j.ijrobp.2009.10.040CrossRefPubMed
44.
Seppenwoolde Y, Wunderink W, Wunderink-van Veen SR, Storchi P, Mendez Romero A, Heijmen BJ: Treatment precision of image-guided liver SBRT using implanted fiducial markers depends on marker-tumour distance. Phys Med Biol 2011,56(17):5445-5468. 10.1088/0031-9155/56/17/001CrossRefPubMed
45.
Oshiro Y, Okumura T, Ishida M, Sugahara S, Mizumoto M, Hashimoto T, Yasuoka K, Tsuboi K, Sakae T, Sakurai H: Displacement of hepatic tumor at time to exposure in end-expiratory-triggered-pulse proton therapy. Radiother Oncol 2011,99(2):124-130. 10.1016/j.radonc.2011.05.009CrossRefPubMed
Metadata
Title
Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution
Authors
Daniel Habermehl
Klaus K Herfarth
Justo Lorenzo Bermejo
Holger Hof
Stefan Rieken
Sabine Kuhn
Thomas Welzel
Jürgen Debus
Stephanie E Combs
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-175

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

Equivalence of Gyn GEC-ESTRO guidelines for image guided cervical brachytherapy with EUD-based dose prescription

Research

A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma

Research

Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy

Research

Molecular basis of ‘hypoxic’ breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling

Research

The stability of osseous metastases of the spine in lung cancer – a retrospective analysis of 338 cases

Research

Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer